Survey of Ophthalmology
Volume 55, Issue 4 , Pages 359-377 , July 2010

Sickle Cell Disease and the Eye: Old and New Concepts

  • Mohammed Elagouz, MD

      Affiliations

    • Laser and Retinal Research Unit, Department of Ophthalmology, King's College Hospital, London, United Kingdom
    • Department of Ophthalmology, Sohag University Hospital, Sohag, Egypt
    • ,
  • Sreedhar Jyothi, MRCOphth

      Affiliations

    • Laser and Retinal Research Unit, Department of Ophthalmology, King's College Hospital, London, United Kingdom
    • ,
  • Bhaskar Gupta, MRCOphth

      Affiliations

    • Laser and Retinal Research Unit, Department of Ophthalmology, King's College Hospital, London, United Kingdom
    • ,
  • Sobha Sivaprasad, DM, MS, FRCS

      Affiliations

    • Laser and Retinal Research Unit, Department of Ophthalmology, King's College Hospital, London, United Kingdom
    • Corresponding Author InformationReprint address: Dr. Sobha Sivaprasad DM, MS, FRCS, Consultant Ophthalmologist, Laser and Retinal Research Unit, Department of Ophthalmology, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom.

References 

  1. Acheson RW, Ford SM, Maude GH, et al. Iris atrophy in sickle cell disease. Br J Ophthalmol. 1986;70:516–521
  2. Acheson RW, Fox PD, Chuang EL, et al. Treatment of iatrogenic choroidal neovascularization in sickle cell disease. Br J Ophthalmol. 1991;75:729–730
  3. Adewoye AH, Ramsey J, McMahon L, et al. Lacrimal gland enlargement in sickle cell disease. Am J Hematol. 2006;81(11):888–889
  4. Aessopos A, Farmakis D, Loukopoulos D. Elastic tissue abnormalities resembling pseudoxanthoma elasticum in beta thalassemia and the sickling syndromes. Blood. 2002;99(1):30–35
  5. Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review. Am J Epidemiol. 2000;151(9):839–845
  6. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995;113:1538–1544
  7. Akinsola FB, Kehinde MO. Ocular findings in sickle cell disease patients in Lagos. Niger Postgrad Med J. 2004;11:203–206
  8. Aluoch JR. Higher resistance to Plasmodiumfalciparum infection in patients with homozygous sickle cell disease in western Kenya. Trap Med Int Health. 1997;2:568–571
  9. Asdourian GK, Nagpal KC, Busse B, et al. Macular and perimacular vascular remodelling in sickling hemoglobinopathies. Br J Ophthalmol. 1976;60:431–453
  10. Babalola OE, Wambebe CO. When should children and young adults with sickle cell disease be referred for eye assessment?. Afr J Med Med Sci. 2001;30(4):261–263
  11. Babalola OE, Wambebe CO. Ocular morbidity from sickle cell disease in a Nigerian cohort. Niger Postgrad Med J. 2005;12(4):241–244
  12. Ballas SK, Lewis CN, Noone AM, et al. Clinical, hematological, and biochemical features of Hb SC disease. Am J Hematol. 1982;13:37–51
  13. Benner JD. Transcorneal oxygen therapy for glaucoma associated with sickle cell hyphema. Am J Ophthalmol. 2000;130(4):514–515
  14. Bergren RL, Brown GC. Neovascular glaucoma secondary to sickle cell retinopathy. Am J Ophthalmol. 1992;113:718–719
  15. Beuzard Y. Mouse models of sickle cell disease. Transfus Clin Biol. 2008;15(1–2):7–11
  16. Blei F, Fancher T, Guarini L. Elevated levels of circulating molecule of potential endothelial cell origins in sickle cell disease. Blood. 1994;84(Suppl):409
  17. Bove JR. Transfusion-transmitted diseases: current problems and challenges. Prog Hematol. 1986;14:123–147
  18. Brittain HA, Eckman JR, Swerlick RA, et al. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vasoocclusion. Blood. 1993;81:2137–2143
  19. Browne PV, Mosher DF, Steinberg MH, et al. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol. 1996;51(4):296–301
  20. Brun M, Bourdoulous S, Couraud PO, et al. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. Pharmacogenomics J. 2003;3(4):215–226
  21. Bunn HF. Disorders of hemoglobin. In:  Braunwald E,  Isselbacher KJ,  Petersdorf RG, et al. editor. Harrison's Principles of Internal Medicine. ed 11. New York: McGraw–Hill; 1987;p. 1518–1523
  22. Cao J, Mathews MK, Mcleod DS, et al. Angiogenic factors in human proliferative sickle cell retinopathy. Br J Ophthalmol. 1999;83:838–846
  23. Carney MD, Jampol LM. Epiretinal membranes in sickle cell retinopathy. Arch Ophthalmol. 1987;105:214–217
  24. Carney MD, Paylor RR, Cunha-Vaz JG, et al. Iatrogenic choroidal neovascularization in sickle cell retinopathy. Ophthalmology. 1986;93:1163–1168
  25. Chambers J, Puglisi J, Kernitsky R, et al. Iris atrophy in hemoglobin SC disease. Am J Ophthalmol. 1974;77:247–249
  26. Chang YP, Maier-Redelsperger M, Smith KD, et al. The relative importance of the X-linked FCP locus and beta-globin haplotypes in determining haemoglobin F levels: a study of SS patients homozygous for beta 5 haplotypes. Br J Haematol. 1997;96:806–814
  27. Clarkson JG. The ocular manifestations of sickle cell disease: a prevalence and natural history study. Tr Am Ophth Soc. 1992;39:481–504
  28. Clarkson JG, Altman RD. Angioid streaks. Surv Ophthalmol. 1982;26:235–246
  29. Coates TD, Fisher TC, Pecsvarady Z, et al. Neutrophil deformability and FcRIII expression are decreased in sickle cell disease patients with clinically severe b globin haplotypes. 18th Annual Meeting —National Sickle Cell Disease Program 93. Philadelphia, PA, 1993, p 63a
  30. Cohen SB, Fletcher ME, Goldberg MF, et al. Diagnosis and management of ocular complications of sickle hemoglobinopathies: Part V. Ophthalmic Surg. 1986;6:369–374
  31. Condon PI, Whitelocke RA, Bird AC, et al. Recurrent visual loss in homozygous sickle cell disease. Br J Ophthalmol. 1985;69(9):700–706
  32. Condon PI, Jampol LM, Ford SM, et al. Choroidal neovascularization induced by photocoagulation in sickle cell disease. Br J Ophthalmol. 1981;65:192–197
  33. Condon PI, Serjeant GR. Ocular findings in homozygous sickle cell anemia in Jamaica. Am J Ophthalmol. 1972;73:533–543
  34. Condon PI, Serjeant GR. Ocular findings in hemoglobin SC disease in Jamaica. Am J Ophthalmol. 1972;74:921–931
  35. Condon PI, Serjeant GR. Photocoagulation and diathermy in the treatment of proliferative sickle retinopathy. Br J Ophthalmol. 1974;58:650–662
  36. Condon PI, Serjeant GR. The progression of sickle cell eye disease in Jamaica. Docum Ophthalmol. 1975;39:203–210
  37. Condon PI, Serjeant GR. Ocular findings in elderly cases of homozygous sickle cell disease in Jamaica. Br J Ophthalmol. 1976;60:361–364
  38. Condon PI, Serjeant GR. Behaviour of untreated proliferative sickle retinopathy. Br J Ophthalmol. 1980;64:404–411
  39. Cruess AF, Stephens RF, Margargal LE, et al. Peripheral circumferential retinal scatter photocoagulation for treatment of proliferative sickle retinopathy. Ophthalmology. 1983;90:272–278
  40. Curran EL, Fleming JC, Rice K, et al. Orbital compression syndrome in sickle cell disease. Ophthalmology. 1997;104:1610–1615
  41. Cusick M, Toma HS, Hwang TS, et al. Binasal visual field defects from simultaneous bilateral retinal infarctions in sickle cell disease. Am J Ophthalmol. 2007;143(5):893–896
  42. Deutsch TA, Weinreb RN, Goldberg MF. Indications for surgical management of hyphema in patients with sickle cell trait. Arch Ophthalmol. 1984;102:566–569
  43. Dizon-Moore RV, Jampol LM, Goldberg MF. Chorioretinal and choriovitreal neovascularization. Arch Ophthalmol. 1981;99:842–849
  44. Dizon RV, Jampol LM, Goldberg MF, et al. Choroidal occlusive disease in sickle cell hemoglobinopathies. Surv Ophthalmol. 1979;23:297–306
  45. Downes SM, Hambleton IR, Chuang EL, et al. Incidence and natural history of proliferative sickle cell retinopathy: observations from a cohort study. Ophthalmology. 2005;112(11):1869–1875
  46. Duits AL, Schnog JB, Lard LR, et al. Elevated IL-8 levels during sickle cell crisis. Eur J Haematol. 1998;61:302–305
  47. Durant WJ, Jampol LM, Daily M. Exudative retinal detachment in hemoglobin SC disease. Retina. 1982;2(3):152–154
  48. Elliott L, Ashley-Koch AE, De Castro L, et al. Genetic polymorphisms associated with priapism in sickle cell disease. Br J Haematol. 2007;137(3):262–267
  49. Emmerson GG, Lutty GA. Effects of sickle cell disease on the eye: clinical features and treatment. Hematol Oncol Clin North Am. 2005;19(5):957–963
  50. Eruchalu UV, Pam VA, Akuse RM. Ocular findings in children with severe clinical symptoms of homozygous sickle cell anaemia in Kaduna, Nigeria. West Afr J Med. 2006;25(2):88–91
  51. Fany A, Boni S, Adjorlolo C, et al. Retinopathy as a sickle cell trait: myth or reality?. J Fr Ophtalmol. 2004;27(9 Pt 1):1025–1030
  52. Fabry ME, Kaul DK. Sickle cell vasoocclusion. Hematol/Oncol Clin N Am. 1991;5:375–398
  53. Fabry ME, Sengupta A, Suzuka SM, et al. A second generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity. Blood. 1995;86(6):2419–2428
  54. Fabry ME, Costantini F, Pachnis A, et al. High expression of human beta S– and alpha-globins in transgenic mice: erythrocyte abnormalities, organ damage, and the effect of hypoxia. Proc Natl Acad Sci USA. 1992;89(24):12155–12159
  55. Fabry ME, Bouhassira EE, Suzuka SM, Nagel RL. Transgenic mice and hemoglobinopathies. Methods Mol Med. 2003;82:213–241
  56. Farber MD, Jampol LM, Fox P, et al. A randomized clinical trial of scatter photocoagulation of proliferative sickle cell retinopathy. Arch Ophthalmol. 1991;109:363–367
  57. Faulborn J, Ardjomand N. Tractional retinoschisis in proliferative diabetic retinopathy: a histopathologic study. Graefes Arch Clin Exp Ophthalmol. 2000;238:40–44
  58. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999;77:527–543
  59. Fine LC, Petrovic V, Irvine AR, et al. Spontaneous central retinal artery occlusion in hemoglobin SC disease. Am J Ophthalmol. 2000;130:680–681
  60. Fink AI, Funahashi T, Robinson M, et al. Conjunctival blood flow in sickle cell disease. Arch Ophthalmol. 1961;66:824–829
  61. Fox PD, Acheson RW, Serjeant GR. Outcome of iatrogenic choroidal neovascularization in sickle cell disease. Br J Ophthalmol. 1990;74:417–420
  62. Fox PD, Dunn DT, Morris JS, et al. Risk factors for proliferative sickle retinopathy. Br J Ophthalmol. 1990;74:172–176
  63. Francis R, Haywood LJ. Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J Natl Med Assoc. 1992;84:611–615
  64. Frank RN, Cronin MA. Posterior pole neovascularization in a patient with hemoglobin SC disease. Am J Ophthalmol. 1979;88:680–682
  65. Gagliano DA, Jampol L, Rabb M. Sickle cell disease. In:  Tasman WS,  Jaeger E editor. Duane's Clinical Ophthalmology. Vol. 3:Philadelphia: Lippincott-Raven Press; 1996;pp 1–38
  66. Gagliano DA, Goldberg MF. The evolution of salmon-patch hemorrhages in sickle cell retinopathy. Arch Ophthalmol. 1989;107:1814–1815
  67. Galinos SO, Asdourian GK, Woolf MB, et al. Choroido-vitreal neovascularization after argon laser photocoagulation. Arch Ophthalmol. 1975;93:524–530
  68. Galinos SO, Asdourian GK, Woolf MB, et al. Spontaneous remodelling of the peripheral retinal vasculature in sickling disorders. Am J Ophthalmol. 1975;79:853–870
  69. Galinos SO, Rabb MF, Goldberg MF, et al. Hemoglobin SC disease and iris atrophy. Am J Ophthalmol. 1973;75:421–425
  70. Ganesh A, Al-Zuhaibi S, Pathare A, et al. Orbital infarction in sickle cell disease. Am J Ophthalmol. 2008;146(4):595–601
  71. Geeraets WJ, Guerry D. Angioid streaks and sickle cell disease. Am J Ophthalmol. 1960;49:450–470
  72. Giardini C, Lucarelli G. Bone marrow transplantation for beta-thalassemia. Hematol Oncol Clin North Am. 1999;13:1059–1064
  73. Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease: Cooperative Study of Sickle Cell Disease. Blood. 1995;86:776–783
  74. Gill HS, Lam WC. A screening strategy for the detection of sickle cell retinopathy in pediatric patients. Can J Ophthalmol. 2008;43:188–191
  75. Goldbaum MH, Fletcher RC, Jampol LM, et al. Cryotherapy of proliferative sickle retinopathy. II. Triple freeze-thaw cycle. Br J Ophthalmol. 1979;63:97–101
  76. Goldbaum MH, Galinos SO, Apple D, et al. Acute choroidal ischemia as a complication of photocoagulation. Arch Ophthalmol. 1976;94:1025–1035
  77. Goldbaum MH, Goldberg MF, Nagpal K, et al. Proliferative sickle retinopathy. In:  L'Esperance F editors. Current Diagnosis and Management of Chorioretinal Disease. St Louis: CV Mosby Co; 1976;p. 132–145
  78. Goldbaum MH, Jampol LM, Goldberg MF. The disc sign in sickling hemoglobinopathies. Arch Ophthalmol. 1978;96:1597–1600
  79. Goldbaum MH, Peyman GA, Nagpal KC, et al. Vitrectomy in sickling retinopathy: report of five cases. Ophthalmic Surg. 1976;7:92–102
  80. Goldbaum MH. Retinal depression sign indicating a small retinal infarct. Am J Ophthalmol. 1978;86(1):45–55
  81. Goldberg MF. Retinal neovascularization in sickle cell retinopathy. Trans Am Acad Ophthalmol Otolaryngol. 1977;83:409–431
  82. Goldberg MF. Natural history of untreated proliferative sickle retinopathy. Arch Ophthalmol. 1971;85:428–437
  83. Goldberg MF. Sickled erythrocytes, hyphema, and secondary glaucoma IV. The rate and percentage of sickling of erythrocytes in rabbit aqueous humor, in vitro and in vivo. Ophthalmic Surg. 1979;10:62–69
  84. Goldberg MF. Sickled erythrocytes, hyphema, and secondary glaucoma I. The diagnosis and treatment of sickled erythrocytes in human hyphemas. Ophthalmic Surg. 1979;10:17–31
  85. Goldberg MF. The diagnosis and treatment of secondary glaucoma after hyphema in sickle cell patients. Am J Ophthalmol. 1979;87:43–49
  86. Goldberg MF, Dizon R, Raichand M. Sickled erythrocytes, hyphema, and secondary glaucoma II. Injected sickle cell erythrocytes into human, monkey, and guinea pig anterior chambers: the introduction of sickling and secondary glaucoma. Ophthalmic Surg. 1979;10:32–51
  87. Goldberg MF, Galinos S, Lee CB, et al. Macular ischemia and infarction in sickling. Invest Ophthalmol. 1973;12:633–635
  88. Goldberg MF, Tso MOM. Rubeosis iridis and glaucoma associated with sickle cell retinopathy: a light and electron microscopic study. Trans Am Acad Ophthalmol Otol. 1978;85:1028–1041
  89. Goodman G, Sallman L, Holland MG. Ocular manifestations of sickle cell disease. Arch Ophthalmol. 1957;58:655–682
  90. Gupta K, Gupta P, Solovey A, Hebbel RP. Mechanism of interaction of thrompospondin with human endothelium and inhibition of sickle erythrocyte adhesion to human endothelial cells by heparin. Biochem Biophys Acta. 1999;1453:63–73
  91. Gurkan E, Tanriverdi K, Baslamish F. Clinical relevance of vascular endothelial growth factor levels in sickle cell disease. Ann Hematol. 2005;84:71–75
  92. Hamilton AM, Pope FM, Condon PI, et al. Angioid streaks in Jamaican patients with homozygous sickle cell disease. Br J Ophthalmol. 1981;65:341–347
  93. Hankins J, Aygun B. Pharmacotherapy in sickle cell disease––state of the art and future prospects. Br J Haematol. 2009;145(3):296–308
  94. Hanscom TA. Indirect treatment of peripheral retinal neovascularization. Am J Ophthalmol. 1982;93:88–91
  95. Harlan JM. Anti-adhesion therapy in sickle cell disease. Blood. 2000;95:365–367
  96. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11(2):129–151
  97. Hebbel RP. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Investig. 1997;100:S83–S86
  98. Hebbel RP. Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies. N Eng J Med. 2000;342:1910–1911
  99. Hedreville M, Connes P, Romana M, et al. Central retinal vein occlusion in a sickle cell trait carrier after a cycling race. Med Sci Sports Exerc. 2009;41(1):14–18
  100. Hirst C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in childrenwith sickle cell disease. Cochrane Database Syst Rev. 2002;(3):CD003427
  101. Hofricher J, Ross PD, Eaton WA. Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. Proc Natl Acad Sci USA. 1974;71:4864–4868
  102. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284:1994–1998
  103. Holash J, Wiegand SJ, Yancopoloulos GD. New model for tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene. 1999;18:5356–5362
  104. Hoppe C, Klitz W, D'Harlingue K, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP) Investigators. Confirmation of an association between the TNF(-308) promoter polymorphism and stroke risk in children with sickle cell anemia. Stroke. 2007;38(8):2241–2246
  105. Hoppe C, Klitz W, Noble J, et al. Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood. 2003;101(7):2865–2869
  106. Isenberg SJ, McRee WE, Jedrzynski MS, et al. Effects of sickle cell anemia on conjunctival oxygen tension and temperature. Arch Intern Med. 1987;147:67–69
  107. Jampol LM, Farber M, Rabb MF, et al. An update on techniques of photocoagulation treatment of proliferative sickle cell retinopathy. Eye. 1991;5(Pt 2):260–263
  108. Jampol LM, Green JL, Goldberg MF, et al. An update on vitrectomy surgery and retinal detachment repair in sickle cell disease. Arch Ophthalmol. 1982;100:591–593
  109. Jampol LM, Condon P, Dizon-Moore R, et al. Salmon patch hemorrhages after central retinal artery occlusion in sickle cell disease. Arch Ophthalmol. 1981;99:237–240
  110. Jampol LM, Goldberg MF. Retinal breaks after photocoagulation of proliferative sickle cell retinopathy. Arch Ophthalmol. 1980;98:676–679
  111. Joneckis CC, Shock DD, Cunningham ML, et al. Glycoprotein IV–independent adhesion of sickle red blood cells to immobilized thrombospondin under flow conditions. Blood. 1996;87:4862–4870
  112. Karaman K, Culic S, Erceg I, et al. Treatment of post-traumatic trabecular mashwork thrombosis and secondary glaucoma with intracameral tissue plasminogen activator in previously unrecognized sickle cell anemia. Coll Antropol. 2005;29(Suppl 1):123–126
  113. Kato GJ, Hebbel RP, Steinberg MH, et al. Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol. 2009;84(9):618–625
  114. Kim SY, Mocanu C, Mcleod DS, et al. Expression of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in sickle cell retina and choroid. Exp Eye Res. 2003;77(4):433–445
  115. Kimmel AS, Magargal LE, Maizel R, et al. Proliferative sickle retinopathy under age 20: a review. Ophthalmic Surg. 1987;18:126–128
  116. Kimmel AS, Margargal LE, Stephens RF, et al. Peripheral circumferential retinal scatter photocoagulation for the treatment of proliferative sickle retinopathy. Ophthalmology. 1986;93:1429–1434
  117. Kimmel AS, Magargal LE, Tasman WS. Proliferative sickle retinopathy and neovascularization of the disc: regression following treatment with peripheral retinal scatter laser photocoagulation. Ophthalmic Surg. 1986;17:20–22
  118. Klein ML, Jampol LM, Condon PI, et al. Central retinal artery occlusion without retrobulbar hemorrhage after retrobulbar anesthesia. Am J Ophthalmol. 1982;93:573–577
  119. Knisely MH, Bloch EH, Eliot TS, Warn , et al. Sludged blood. Science. 1947;106:431–440
  120. Konotey-Ahulu FID. The sickle cell diseases: clinical manifestations including the “sickle crisis”. Arch Intern Med. 1974;133:611–619
  121. Lanaro C, Franco-Penteado CF, Albuqueque DM, et al. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol. 2009;85(2):235–242
  122. Lard LR, Mul FP, de Haas M, et al. Neutrophil activation in sickle cell disease. J Leukoc Biol. 1999;66:411–415
  123. Lasky LA. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science. 1992;258:964–969
  124. Lee CB, Woolf MB, Galinos SO, et al. Cryotherapy of proliferative sickle retinopathy. Part I. Single freeze-thaw cycle. Ann Ophthalmol. 1975;7:1299–1308
  125. Lee CM, Charles HC, Smith RT, et al. Quantification of macular ischemia in sickle cell retinopathy. Br J Ophthalmol. 1987;71:540–545
  126. Leen JS, Ratnakaram R, Del Priore LV, et al. Anterior segment ischemia after vitrectomy in sickle cell disease. Retina. 2002;22:216–219
  127. Levasseur DN, Ryan TM, Pawlik KM, et al. Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood. 2003;102:4312–4319
  128. Liang JC, Jampol LM. Spontaneous peripheral chorioretinal neovascularization in association with sickle cell anemia. Br J Ophthalmol. 1983;67:107–110
  129. Lima CS, Rocha EM, Silva NM, et al. Risk factors for conjunctival and retinal vessel alterations in sickle cell disease. Acta Ophthalmol Scand. 2006;84(2):234–241
  130. Locatelli F. Related umblical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood. 2003;101:2137–2143
  131. Lorey FW, Arnopp J, Cunningham GC. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state. Genet Epidemiol. 1996;13:501–512
  132. Lowry WE, Richter L, Yachechko R, et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci USA. 2008;105:2883–2888
  133. Lu M, Perez VL, Ma N. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci. 1999;40:1808–1812
  134. Lutty GA, Goldberg MF. Ophalmological complications. In:  Embury SH,  Hebbel RP,  Mohandas N, et al. editor. Sickle Cell Disease: Basic Principles and Clinical Practice. New York: Raven Press; 1994;p. 703–724
  135. Lutty GA, Otsuji T, Taomoto M, et al. Mechanisms for sickle red blood cell retention in choroid. Curr Eye Res. 2002;25(3):163–171
  136. Lutty GA, Merges C, McLeod DS, et al. Nonperfusion of retina and choroid in transgenic mouse models of sickle cell disease. Curr Eye Res. 1998;17(4):438–444
  137. Lutty GA, Phelan A, McLeod DS, et al. A rat model for sickle cell–mediated vaso-occlusion in retina. Microvasc Res. 1996;52(3):270–280
  138. Lutty GA, McLeod DS, Pachnis A, et al. Retinal and choroidal neovascularization in a transgenic mouse model of sickle cell disease. Am J Pathol. 1994;145(2):490–497
  139. Lutty GA, Merges C, Crone S, et al. Immunohistochemical insights into sickle cell retinopathy. Curr Eye Res. 1994;13(2):125–138
  140. Lutty GA, Taomoto M, Cao J, McLeod DS, et al. Inhibition of TNF-alpha-induced sickle RBC retention in retina by a VLA-4 antagonist. Invest Ophthalmol Vis Sci. 2001;42(6):1349–1355
  141. Madigan C, Malik P. Pathophysiology and therapy for haemoglobinopathies. Part I: sickle cell disease. Expert Rev Mol Med. 2006;8(9):1–23
  142. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science. 1997;277:55–60
  143. Malave I, Perdomo Y, Escalona E, et al. Levels of tumor necrosis factor a/cachectin (TNFa) in sera from patients with sickle cell disease. Acta Haematol. 1993;90:172–176
  144. Mandriota SJ, Pepper MS. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res. 1998;83:852–859
  145. Marcus RE, Bolger JP, Roderick PJ, et al. Central retinal artery occlusion in homozygous sickle cell (SS) disease. Clin Lab Haematol. 1988;10:467–470
  146. Marsh RJ, Ford SM, Rabb MF, et al. Macular vasculature, visual acuity and irreversibly sickled cells in homozygous sickle cell disease. Br J Ophthalmol. 1982;66:155–160
  147. Mason JO. Surgical closure of macular hole in association with proliferative sickle cell retinopathy. Retina. 2002;22(4):501–502
  148. Mathews MK, McLeod DS, Merges C, et al. Neutrophils and leucocyte adhesion molecules in sickle cell retinopathy. Br J Ophthalmol. 2002;86:684–690
  149. McLeod DS, Merges C, Fukushima A, et al. Histopathologic features of neovascularization in sickle cell retinopathy. Am J Ophthalmol. 1997;124(4):455–472
  150. McLeod DS, Goldberg MF, Lutty GA. Dual-perspective analysis of vascular formations in sickle cell retinopathy. Arch Ophthalmol. 1993;111(9):1234–1245
  151. Mehta JS, Whittaker KW, Tsaloumas MD. Latent proliferative sickle cell retinopathy in sickle cell trait. Acta Ophthalmol Scand. 2001;79:81–82
  152. McLane NJ, Grizzard WS, Kousseff BG, et al. Angioid streaks associated with hereditary spherocytosis. Am J Ophthalmol. 1984;97:444–449
  153. Miller CL, Imren S, Antonchuk J, et al. Feasibility of using autologous transplantation to evaluate hematopoietic stem cell–based gene therapy strategies in transgenic mouse models of human disease. Mol Ther. 2002;6(3):422–428
  154. Minatoya H, Acacio I, Goldberg M. Fluorescein angiography of the bulbar conjunctiva in sickle cell disease. Ann Ophthalmol. 1973;5:908–992
  155. Mohan JS, Lip PL, Blann AD, et al. The angiopoietin/Tie-2 system in proliferative sickle retinopathy: relation to vascular endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of laser treatment. Br J Ophthalmol. 2005;89:815–819
  156. Moore C, Ehlayel M, Leiva L, et al. New concepts in the immunology of sickle cell disease. Ann Allergy Asthma Immunol. 1996;76:385–403
  157. Morgan DM, D'Amico DJ. Vitrectomy surgery in proliferative sickle retinopathy. Am J Ophthalmol. 1987;104:133–138
  158. Moriarty BJ, Acheson RW, Condon PI, et al. Patterns of visual loss in untreated sickle cell retinopathy. Eye. 1988;2(Pt 3):330–335
  159. Moriarty BJ, Acheson RW, Serjeant GR. Epiretinal membranes in sickle cell disease. Br J Ophthalmol. 1987;71:466–469
  160. Moriarty BJ, Webb DK, Serjeant GR. Treatment of subretinal neovascularization associated with angioid streaks in sickle cell retinopathy. Arch Ophthalmol. 1987;105:1327–1328
  161. Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program. 2008;177–185
  162. Mozzarelli A, Hofricher J, Eaton WA. Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. Science. 1987;237:500–506
  163. Nagel RL, Ranney HM. Genetic epidemiology of structural mutations of the beta-globin gene. Semin Hematol. 1990;27:342–359
  164. Nagel RL, Fabry ME, Steinberg MH. The paradox of hemoglobin SC disease. Blood Rev. 2003;17(3):167–178
  165. Nagel RL, Fabry ME. The panoply of animal models for sickle cell anaemia. Br J Haematol. 2001;112(1):19–25
  166. Nagpal KC, Goldberg MF, Rabb MF. Ocular manifestations of sickle hemoglobinopathies. Surv Ophthalmol. 1977 Mar–Apr;21(5):391–411
  167. Nagpal KC, Asdourian G, Goldbaum M, et al. Angioid streaks and sickle hemoglobinopathies. Br J Ophthalmol. 1976;60:31–34
  168. Nagpal KC, Patrianakos D, Asdourian GK, et al. Spontaneous regression (autoinfarction) of proliferative sickle retinopathy. Am J Ophthalmol. 1975;80:885–892
  169. Nagpal KC, Asdourian GK, Patrianakos D, et al. Proliferative retinopathy in sickle cell trait. Arch Intern Med. 1977;137:325–328
  170. Oh H, Takagi H, Suzuma K, et al. Hypoxia and vascular endothelial growth factor selectively upregulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem. 1999;274:15732–15739
  171. Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008;451:141–146
  172. Paszty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997;278:876–878
  173. Paton D. The conjunctival sign of sickle cell disease. Arch Ophthalmol. 1961;66:90–94
  174. Paton D. The conjunctival sign of sickle cell disease: further observations. Arch Ophthalmol. 1962;68:627–632
  175. Pawlik R, Westerman KA, Fabry ME, et al. Correction of of sickle cell disease in transgenic mouse models by gene therapy. Science. 2001;294:2368–2371
  176. Peachey NS, Charles HC, Lee CM, et al. Electroretinographic findings in sickle cell retinopathy. Arch Ophthalmol. 1987;105:934–938
  177. Peachey NS, Gagliano DA, Jacobson MS, et al. Correlation of electroretinographic findings and peripheral retinal nonperfusion in patients with sickle cell retinopathy. Arch Ophthalmol. 1990;108:1106–1109
  178. Penman AD, Talbot JF, Chuang EL, et al. New classification of peripheral retinal vascular changes in sickle cell disease. Br J Ophthalmol. 1994;78:681–689
  179. Perelman N, Selvaraj SK, Batra S, et al. Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood. 2003;102:1506–1514
  180. Perlman JI, Forman S, Gonzalez ER. Retrobulbar ischemic optic neuropathy associated with sickle cell disease. J Neuro-Ophthalmol. 1994;14:45–48
  181. Powars D, Hiti A. Sickle cell anemia: beta s gene cluster haplotypes as genetic markers for severe disease expression. Am J Dis Child. 1993;147:1197–1202
  182. Procianoy F, Brandão Filho M, Cruz AA, et al. Subperiosteal hematoma and orbital compression syndrome following minor frontal trauma in sickle cell anemia: case report. Arq Bras Oftalmol. 2008;71(2):262–264
  183. Pulido JS, Flynn HW, Clarkson JG, et al. Pars plana vitrectomy in the management of complications of proliferative sickle retinopathy. Arch Ophthalmol. 1988;106:1553–1557
  184. Raichand M, Dizon RV, Nagpal KC, et al. Macular holes associated with proliferative sickle cell retinopathy. Arch Ophthalmol. 1987;96:1592–1596
  185. Rednam KRV, Jampol LM, Goldberg MF. Scatter retinal photocoagulation for proliferative sickle cell retinopathy. Am J Ophthalmol. 1982;93:594–599
  186. Ribeiro JA, Lucena D da R, Lucena L da R, et al. Proliferative sickle cell retinopathy associated with sickle cell trait and gestational diabetes: case report. Arq Bras Oftalmol. 2009;72(3):400–402
  187. Rodgers GP, Roy MS, Noguchi C, et al. Is there a role for selective vasodilation in the management of sickle cell disease?. Blood. 1988;71:597–602
  188. Romayananda N, Goldberg MF, Green WR. Histopathology of sickle cell retinopathy. Trans Am Acad Ophthalmol Otol. 1973;77:652–676
  189. Roth SE, Magargal LE, Kimmel AS, et al. Central retinal artery occlusion in proliferative sickle cell retinopathy after retrobulbar injection. Ann Ophthalmol. 1988;20:221–224
  190. Roy MS, Gascon P, Giuliani D. Macular blood flow velocity in sickle cell disease, relation to red cell density. Br J Ophthalmol. 1995;79:742–745
  191. Roy MS, Rodgers G, Gunkel R, et al. Color vision defects in sickle cell anemia. Arch Ophthalmol. 1987;105:1676–1678
  192. Ryan SJ, Goldberg MF. Anterior segment ischemia following scleral buckling in sickle cell hemoglobinopathy. Am J Ophthalmol. 1971;72:35–50
  193. Ryan SJ. Occlusion of the macular capillaries in sickle cell hemoglobin C disease. Am J Ophthalmol. 1974;77:459–461
  194. Saleh AW, Hillen HF, Duits AJ. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol. 1999;102:31–37
  195. Sanders RJ, Brown GC, Rosenstein RB, et al. Foveal avascular zone diameter and sickle cell disease. Arch Ophthalmol. 1991;109(6):812–815
  196. Sayag D, Binaghi M, Souied EH, et al. Retinal photocoagulation for proliferative sickle cell retinopathy: a prospective clinical trial with new sea fan classification. Eur J Ophthalmol. 2008;18(2):248–254
  197. Schubert HD. Schisis in sickle cell retinopathy. Arch Ophthalmol. 2005;123:1607–1609
  198. Seiberth V. Transscleral diode laser photocoagulation in proliferative sickle cell retinopathy. Ophthalmology. 1999;106(9):1828–1829
  199. Serjeant GR. The Clinical Features of Sickle Cell Disease. New York: Elsevier; 1974;
  200. Serjeant GR, Serjeant BE. Nomenclature and genetics of sickle cell disease. In:  Serjeant GR,  Serjeant BE editor. Sickle Cell Disease. ed 3. Oxford: Oxford University Press; 2001;p. 31–40
  201. Serjeant GR, Serjeant BE. The eyes. In:  Serjeant GR,  Serjeant BE editor. Sickle Cell Disease. ed 3. Oxford: Oxford University Press; 2001;p. 366–392
  202. Shaikh S. Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy. Indian J Ophthalmol. 2008;56:259
  203. Shields JA, Federman JL, Tomer TL, et al. Angioid streaks, I. Ophthalmoscope variations and diagnostic problems. Br J Ophthalmol. 1975;59:257–266
  204. Shima DT, Deutsch U, D'Amore P. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett. 1995;370:203–208
  205. Sidman JD, Brownlee RE, Smith WC, et al. Orbital complications of sickle cell disease. Internat J Pediat Otorhinolaryngol. 1990;169:181–184
  206. Singerman LJ. Angioid streaks in thalassemia. Br J Ophthalmol. 1983;67:558
  207. Siqueira RC, Costa RA, Scott IU, et al. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol Scand. 2006;84:834–835
  208. Smith RE, Wise K, Kingsley RM. Idiopathic polypoidal choroidal vasculopathy and sickle cell retinopathy. Am J Ophthalmol. 2000;129(4):544–546
  209. Solovey A, Gui L, Ramakrishnan S, et al. Sickle cell anemia as a possible state of enhanced anti–apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. Blood. 1999;93(11):3824–3830
  210. Steinberg MH, Thein SL. Genetic Modulation of sickle cell disease. In:  Pace BS editors. Renaissance of Sickle Cell Disease Research in the Genome Era. London: Imperial College Press; 2007;p. 193–206
  211. Stevens TS, Busse B, Lee CB, et al. Sickling hemoglobinopathies. Macular and perimacular vascular abnormalities. Arch Ophthalmol. 1974;92:455–463
  212. Stuart MJ, Settty BN. Sickle cell acute chest syndrome: pathogenesis and rationale for therapy. Blood. 1999;95:1555–1560
  213. Sugihara K, Sugihara T, Mohandas N, et al. Thrombospondin mediates adherence of CD36+ sickle erythrocytes to endothelial cells. Blood. 1992;80:2634–2642
  214. Swerlick R, Eckman J, Kumar A, et al. Alpha 4 beta 1 expression on sickle reticulocytes: vascular cell adhesion molecule 1 dependent binding to the endothelium. Blood. 1993;82:1891–1899
  215. Taban M, Sears JE, Crouch E, et al. Acute idiopathic frosted branch angiitis. J AAPOS. 2007;11(3):286–287
  216. Takagi H, Koyama S, Seike H, et al. Potential role of angiopoietin/Tie-2 system in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:393–402
  217. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–676
  218. Talbot AF, Bird AC, Maude GH, et al. Sickle cell retinopathy in Jamaican children: fyrther observation from a cohort study. Br J Ophthalmol. 1988;72:727–732
  219. Talbot AF, Bird AC, Rabb LM, et al. Sickle cell retinopathy in Jamaican children: a search for prognostic factors. Br J Ophthalmol. 1983;67:782–785
  220. Talbot JF, Bird AC, Serjeant GR, et al. Sickle cell retinopathy in young children in Jamaica. Br J Ophthalmol. 1982;66:149–154
  221. Thomas PW, Higgs DR, Serjeant GR. Benign clinical course in homozygous sickle cell disease: a search for predictors. J Clin Epidemiol. 1997;50:121–126
  222. Townes TM. Gene replacement therapy for sickle cell disease and other blood disorders. Hematology Am Soc Hematol Educ Program. 2008;193–196
  223. Traoré J, Boitre JP, Bogoreh IA, et al. Sickle cell disease and retinal damage: a study of 38 cases at the African Tropical Ophthalmology Institute (IOTA) in Bamako. Med Trop (Mars). 2006;66(3):252–254
  224. Trudel M, De Paepe ME, Chrétien N, et al. Sickle cell disease of transgenic SAD mice. Blood. 1994;84(9):3189–3197
  225. Vichinsky E. New therapies in sickle cell disease. Lancet. 2002;360(9333):629–631
  226. Wajer SD, Taomoto M, McLeod DS, et al. Velocity measurements of normal and sickle red blood cells in the ratretinal and choroidal vasculatures. Microvasc Res. 2000;60(3):281–293
  227. Wallow IHL, Davis MD. Clinicopathologic correlation of xenon arc and argon laser photocoagulation. Arch Ophthalmol. 1979;97:2308–2314
  228. Welch RB, Goldberg MF. Sickle-cell hemoglobin and its relation to fundus abnormality. Arch Ophthalmol. 1966;75:353–362
  229. Williamson TH, Rajput R, Laidlaw DAH, Mokete B. Vitreoretinal management of the complications of sickle cell retinopathy by observation or pars plana vitrectomy. Eye. 2008;296:1–7
  230. Witkin AJ, Rogers AH, Ko TH, et al. Optical coherence tomography demonstration of macular infarction in sickle cell retinopathy. Arch Ophthalmol. 2006;124(5):746–747
  231. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic Biol Med. 2008;44(8):1506–1528
  232. Wun T, Paglieroni T, Field CL, et al. Platelet–erythrocyte adhesion in sickle cell disease. J Investig Med. 1999;47:121–127
  233. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917–1920
  234. Zimmerman SA, O'Branski EE, Rosse WF, et al. Hemoglobin S/O(Arab): thirteen new cases and review of the literature. Am J Hematol. 1999;60(4):279–284

 The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article.

PII: S0039-6257(09)00307-5

doi: 10.1016/j.survophthal.2009.11.004

Survey of Ophthalmology
Volume 55, Issue 4 , Pages 359-377 , July 2010

Article Tools